20/05/2022at 10:59

Ambu board had started headhunting process long before firing of CEO

Thursday’s CEO change had been in the works for a while, says Ambu’s board chair Jørgen Jensen.

With Chairman of Ambu Jørgen Jensen at the helm, the company's board decided to lay off chief executive Juan Jose Gonzalez on Thursday | Photo: Ida Munch/ERH

by andreas lønstrup, translated by catherine brett & daniel pedersen

Disappointing financial results and seven guidance downgrades ate away at the confidence the Ambu board had in CEO Juan Jose Gonzalez, says Ambu chairman Jørgen Jensen on the CEO’s last day in the role. Gonzalez was CEO at the company for just over three years.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

Access all locked articles
Receive our daily newsletters
Access our app

Get full access for you and your coworkers

Start a free company trial today

Ambu appoints Britt Meelby Jensen new CEO
For subscribers
Ambu to reign in expectations after seventh downgrade since 2019
For subscribers
Ambu downgrades financial guidance
For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Front page now

Pharma & biotech

Adolescent patients' eczema improved in Leo Pharma's late-stage testing

Two phase III trials give the Danish dermatology company hope to see tralokinumab’s approved indication expanded to include the younger segment of teens.

For subscribers

Hearing health

DNB surprised by GN's lack of backup plan

For subscribers

Pharma & biotech

Leo Pharma presents positive data in hand eczema phase III trial

For subscribers

Foto: Guillaume Souvant/Reuters/Ritzau Scanpix

Pharma & biotech

Six-month Ozempic shortage mostly over after weight-loss craze drained supply

For subscribers

Foto: Tingshu Wang/Reuters/Ritzau Scanpix

Regulation

Competition sharpens on active ingredient production – EU weighs measures

For subscribers

Pharma & biotech

Wegovy prescriptions in the US grow for another week

For subscribers

Ambu opens up about stalled Russian exit

Although the Danish medtech company still isn’t fully transparent about its process of leaving the Russian market, CEO Britt Meelby Jensen now names two of the challenges.

For subscribers

Foto: Jacob Gronholt-Pedersen/Reuters/Ritzau Scanpix

Pharma & biotech

Novo Nordisk reacts to suspension: "We take the decision very seriously"

Novo Nordisk, which has been ousted from UK pharma group ABPI for two years, does not want to comment further on its punishment for misleading marketing.

For subscribers

Pharma & biotech

UK pharma group suspends Novo Nordisk for two years

Novo Nordisk has been suspended due to misleading marketing that breached the Code of Practice of the Association of the British Pharmaceutical Industry.

For subscribers